[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-cardiomyopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,77,99,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053768","atrial-cardiomyopathy-in-patients-with-cardiovascular-kidney-metabolic-syndrome-non-invasive-characterization-100053768",false,"NCT07697469","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization (ATRIO-CKM)","ATRIO-CKM","Inclusion Criteria:\n\n* Adults aged 18 years or older presenting for cardiovascular evaluation Signed written informed consent Agreement with all protocol requirements\n\nExclusion Criteria:\n\n* Missing key data for ACM or CKM classification Hemodynamically significant valvular heart disease (greater than moderate severity) Mechanical or biological valve prostheses Temporary or permanent cardiac pacing Psychiatric pathology Thyroid pathology (active or untreated) Known cardiomyopathies (hypertrophic, dilated, restrictive, or infiltrative) Refusal to participate or inability to comply with protocol requirements","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multiorgan dysfunction and increased risk of atrial fibrillation, stroke, and heart failure. Atrial cardiomyopathy (ACM) - defined as any structural, contractile, or electrical abnormality of the atria - is an increasingly recognized contributor to cardiovascular morbidity and mortality in this population. Despite growing interest in both conditions, their interplay remains poorly understood, limiting effective preventive strategies and risk-stratification approaches for this high-risk group.\n\nCKM staging offers a practical framework for anticipating ACM onset and progression. Because adiposity-driven inflammation, insulin resistance, hypertension, and early kidney injury act as upstream drivers in CKM, the left atrium becomes an early indicator of hemodynamic load and fibrosis - often preceding sustained atrial fibrillation. Early non-invasive detection of ACM across CKM stages could shift care from treating complications to modifying the underlying substrate.\n\nThis prospective observational single-center cohort study aims to phenotype ACM non-invasively across all CKM stages at first diagnosis, using standard 12-lead ECG, advanced transthoracic echocardiography with speckle-tracking, a mechanistically selected biomarker panel (NT-proBNP, MR-proANP, Fetuin-A, FGF23), and cardiac MRI.\n\nAdults aged 18 years or older presenting for cardiovascular evaluation are enrolled and grouped as CKM with ACM (study group) versus CKM without ACM (control group). All participants undergo a single standardized baseline evaluation including clinical examination, 12-lead ECG with Bayés interatrial block grading, comprehensive laboratory panel, and advanced echocardiography including left atrial global longitudinal strain by speckle-tracking.\n\nPrimary objective: characterize the relationship between ACM and CKM syndrome stages using non-invasive parameters at first diagnosis. Secondary objectives include assessment of clinical, biological, ECG, and imaging profiles of ACM in CKM; evaluation of left atrial function across CKM stages; examination of Bayés interatrial block correlations and the impact of SGLT2 inhibitors and GLP-1 receptor agonists on left atrial remodeling in HFpEF; and identification of independent ACM risk factors incorporating the full biomarker panel.\n\nStatistical analyses include multivariable logistic regression, biomarker ROC analyses, and penalized regression for derivation of a pragmatic ACM risk score with internal validation. Expected outputs include prevalence estimates, effect sizes for ACM and CKM joint categories, biomarker performance metrics, and a clinic-ready checklist for risk-stratified prevention in outpatient settings.",[25,26,27,28,29],"Cardiovascular-Kidney-Metabolic Syndrome","Atrial Cardiomyopathy","Atrial Fibrillation","Chronic Kidney Disease","Metabolic Syndrome",[31,32,33,34,35,36,37,38,39,27,28],"atrial cardiomyopathy","CKM syndrome","on-invasive evaluation","atrial remodeling","Bayés interatrial block","speckle tracking","Fetuin-A","MR-proANP","FGF23","NOT_YET_RECRUITING","2026-07-05",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":21},"2026-07-10",{"date":48,"type":21},"2028-04",{"name":50,"class":51},"Grigore T. Popa University of Medicine and Pharmacy","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":52},"100642550","association-between-circulating-bdnf-levels-and-atrial-cardiomyopathy-in-patients-undergoing-ablation-for-persistent-atrial-fibrillation-100642550","NCT07648329","Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation","METAPROFIL 2","Inclusion Criteria:\n\n* Participants who have provided written consent\n* Patients aged 18 years or older.\n* Patients scheduled to undergo their first ablation procedure for persistent atrial fibrillation at the Dijon Bourgogne University Hospital\n\nExclusion Criteria:\n\n* A person who is not enrolled in or eligible for a social security program\n* A person subject to a legal protective measure (guardianship, conservatorship)\n* Person subject to a judicial safeguard measure\n* Pregnant or breastfeeding woman\n* Adult who is legally incapacitated or unable to give consent\n* Ablation of paroxysmal AF with or without electroanatomical mapping",{"count":61,"type":21},150,"trial fibrillation (AF) is the most common cardiac arrhythmia worldwide, and its prevalence continues to rise. AF is associated with serious complications, including embolic strokes, heart failure, and mortality. Characterized by rapid, irregular, and weakened contractions of the atria, AF is considered one of the \"visible\" electrophysiological manifestations of a broader condition known as atrial cardiomyopathy (ACM). Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, predisposes to thrombus formation. Once dislodged from the atrial cavity and migrating to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for ACI\u002FAF are metabolic syndrome and aging. CMA is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, we aim to address this challenge by approaching CMA through one of its complications: persistent atrial fibrillation. Indeed, CMA can be assessed using electroanatomical mapping during atrial fibrillation ablation (AFA) procedures. During radiofrequency ablation of AF, electroanatomical mapping of the left atrium is performed to measure left atrial voltage, which serves as an indirect marker of the presence of atrial fibrosis, strongly associated with CMA. Other parameters relevant to the identification of CMA can be assessed during this procedure, such as conduction velocities and specific electrographic characteristics.\n\nWe plan to include 150 patients undergoing ablation for persistent atrial fibrillation at the Dijon Bourgogne University Hospital and to correlate circulating levels of BDNF (brain-derived neurotrophic factor) with electroanatomical mapping data of the left atrium. The electrical remodeling of the left atrium, including low-voltage areas and conduction velocity, as well as left atrial morphology assessed by pre-procedural cardiac computed tomography using the ADAS3 Galgo LA Module software, will be correlated with BDNF levels. Blood samples for BDNF assessment will be collected before or at the start of the ablation procedure, prior to any catheter insertion into the vessels.\n\nWhile investigating the association between BDNF levels and CMA characteristics during AF ablation, thereby confirming the pathophysiological relationship with atrial remodeling, our objective is also to evaluate the prognostic role of BDNF levels in clinical and rhythm outcomes following AF ablation. Thus, we will compare changes in BDNF levels after AF ablation at one-year follow-up, correlating them with the evolution of CMA-based on left atrial parameters assessed by echocardiography or cardiac computed tomography-autonomic nervous system balance and heart rhythm obtained via Holter monitoring, as well as clinical outcomes.",[64,65,66,67,26],"Atrial Fibrillation (AF)","Cardiac Arrhythmia","Atrial Fibrillation Ablation","BDNF","2026-06-10",{"date":70,"type":44},"2026-06-15",{"date":72,"type":21},"2026-07",{"date":74,"type":21},"2029-07",{"name":76,"class":51},"Centre Hospitalier Universitaire Dijon",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":52},"100593684","prognostic-role-of-ai-echo-100593684","NCT07009639","Prognostic Role of AI-Echo","Evaluation of Artificial Intelligence-Assisted Echocardiography (AI-echo) in the Early Diagnosis and Prognostic Stratification of Left Atrial Cardiomyopathy (LACM) in Patients With Acute Cardiac Disease","Inclusion Criteria:\n\n1. Age between 18 and 85 years.\n2. Hospitalization in CCU for acute cardiac pathology (e.g. acute coronary syndrome, acute or exacerbated heart failure, malignant arrhythmias, etc.).\n3. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe hemodynamic instability, history to contraindicate the execution of the echocardiographic examination.\n2. Severely inadequate echocardiographic window that precludes atrial or ventricular morpho-functional assessment.\n3. Inability to continue the study for clinical reasons, logistics or patient refusal.","85 Years",{"count":86,"type":21},45,"Left atrial cardiomyopathy (LACM) is frequently underdiagnosed but plays a key role in increasing the risk of atrial fibrillation (AF) and thromboembolic events. While atrial strain is a validated marker of LACM, its measurement with conventional echocardiography can be time-consuming and less feasible in acute settings. The use of AI-assisted echocardiography (AI-echo) may help streamline image acquisition and analysis, offering faster and potentially more accurate assessment.\n\nThis study aims to compare the time required for atrial strain analysis using AI-echo versus standard methods. It also explores how changes in strain parameters (LASr, LASct, LAScd) relate to the onset of AF and in-hospital adverse outcomes, adjusting for comorbidities and conventional echo variables.\n\nMain endpoints include time reduction with AI-echo and the association between strain changes and AF, complications, or mortality during hospitalization.",[26],"RECRUITING","2025-08-06",{"date":92,"type":44},"2025-08-11",{"date":94,"type":44},"2025-07-01",{"date":96,"type":21},"2025-11-30",{"name":98,"class":51},"University of Calabria",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":123,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":52},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",true,{"count":109,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[113,27,114,115,116,117,118,119,120,121,122,26],"Arrhythmias, Cardiac","Atrial Flutter","Ventricular Tachycardia","Atrial Tachycardia","Arrhythmogenic Right Ventricular Dysplasia","Long QT Syndrome","Brugada Syndrome","Supraventricular Tachycardia","Catecholaminergic Polymorphic Ventricular Tachycardia","Torsades De Pointes",[124,125,65,126,127,128,26],"Catheter Ablation","Biomarkers","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":131,"type":44},"2025-03-30",{"date":133,"type":44},"2021-03-17",{"date":135,"type":21},"2031-12-31",{"name":137,"class":51},"Universitätsklinikum Hamburg-Eppendorf",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":52},"100531477","atrial-fibrillation-af-ablation-to-prevent-disease-progression-of-af-induced-atrial-cardiomyopathy-in-women-and-men-100531477","NCT06200311","Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men","RACE X","Inclusion criteria\n\n* Confirmed ACMP (LAVI \\>34 ml\u002Fm2)\n* ECG-confirmed AF\n* Age: 65-80 years old\n* Patients eligible for both treatment strategies judged by the treating physician signed and dated informed consent prior to admission to the trial\n\nExclusion criteria\n\n* Longstanding (\\>1 year) persistent or permanent (accepted) AF\n* Previous left atrial (LA) ablation or LA surgery\n* AF due to a reversible cause (e.g. hyperthyroidism, post-operative AF)\n* Recent (\\\u003C90 days) acute coronary syndrome, stroke\u002FTIA or cardiac intervention (Cardiac interventions include percutaneous coronary intervention, coronary artery bypass grafting, and heart valve repair or replacement (endovascular or surgical))\n* Intracardiac thrombus\n* HF NYHA III\u002FIV\n* Impaired renal function, defined as estimated glomerular filtration rate ≤25 ml\u002Fmin\u002F1.73m2\n* Presence of (or scheduled for) mechanical assist device or heart transplant\n* Severe aortic or mitral valve disease\n* Complex congenital heart disease\n* Life expectancy \\\u003C1 year\n* Currently enrolled in another clinical randomized trial","65 Years","80 Years",{"count":148,"type":21},604,"INTERVENTIONAL",[151],"NA","The goal of clinical trial is to compare AF ablation to pharmacological rhythm management (being rate or rhythm control) in AF patients with signs of atrial cardiomyopathy (as defined by left atrial volume index \\>34 ml\u002Fm2) The main objective it aims to answer is to determine whether AF ablation compared to pharmacological rhythm management in ACMP patients with AF reduces the incidence of the composite primary endpoint of CV death and first CV hospitalization\u002Furgent visit.",[154,26],"Fibrillation, Atrial",[156,157,158,31,159],"pulmonary vein isolation","mHealth","atrial fibrillation","AF ablation","2024-10-16",{"date":162,"type":44},"2024-10-18",{"date":164,"type":44},"2024-07-25",{"date":166,"type":21},"2029-07-25",{"name":168,"class":51},"University Medical Center Groningen"]